Best Biotech Stocks To Follow Now - July 19th

Thermo Fisher Scientific, AbbVie, Danaher, Veeva Systems, Vertex Pharmaceuticals, IQVIA, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are equity shares of companies that apply biological science and technology—such as genetic engineering, cell therapies, and molecular diagnostics—to develop medical treatments, diagnostics, and other life-science products. These firms typically devote a large share of their budgets to research and development and must navigate lengthy regulatory approval processes. As a result, biotech stocks can be highly volatile and risky, but they also offer the potential for substantial returns if a company’s pipeline products achieve commercial success. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Shares of Thermo Fisher Scientific stock traded down $9.69 during trading on Friday, hitting $415.29. 2,647,234 shares of the company were exchanged, compared to its average volume of 2,021,614. The firm has a market capitalization of $156.77 billion, a P/E ratio of 24.36, a price-to-earnings-growth ratio of 2.26 and a beta of 0.77. The firm's fifty day moving average price is $410.38 and its 200 day moving average price is $473.00. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38. Thermo Fisher Scientific has a 1-year low of $385.46 and a 1-year high of $627.88.

Read Our Latest Research Report on TMO

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

ABBV stock traded down $2.14 during midday trading on Friday, hitting $189.26. 5,331,983 shares of the company's stock were exchanged, compared to its average volume of 6,318,509. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.64 and a current ratio of 0.76. The stock's fifty day moving average price is $187.17 and its 200-day moving average price is $189.38. AbbVie has a one year low of $163.81 and a one year high of $218.66. The company has a market cap of $334.31 billion, a PE ratio of 80.54, a price-to-earnings-growth ratio of 1.27 and a beta of 0.48.

Read Our Latest Research Report on ABBV

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

DHR stock traded down $4.81 during trading hours on Friday, reaching $189.98. 4,239,169 shares of the stock were exchanged, compared to its average volume of 3,521,325. The firm's 50-day moving average is $196.13 and its 200-day moving average is $205.20. Danaher has a 12 month low of $171.00 and a 12 month high of $281.70. The company has a market cap of $135.96 billion, a price-to-earnings ratio of 36.89, a PEG ratio of 2.73 and a beta of 0.77. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.43 and a quick ratio of 1.05.

Read Our Latest Research Report on DHR

Veeva Systems (VEEV)

Veeva Systems Inc. provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.

Shares of NYSE VEEV traded up $5.57 during midday trading on Friday, reaching $282.03. The company's stock had a trading volume of 1,752,655 shares, compared to its average volume of 1,175,309. The stock has a 50 day simple moving average of $270.48 and a 200-day simple moving average of $241.68. Veeva Systems has a fifty-two week low of $177.41 and a fifty-two week high of $291.69. The stock has a market capitalization of $46.09 billion, a price-to-earnings ratio of 59.75, a PEG ratio of 2.19 and a beta of 0.98.

Read Our Latest Research Report on VEEV

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Shares of Vertex Pharmaceuticals stock traded down $3.46 during trading on Friday, hitting $459.81. 975,143 shares of the stock were exchanged, compared to its average volume of 1,420,625. The company has a fifty day moving average price of $449.49 and a 200-day moving average price of $462.47. The stock has a market capitalization of $118.08 billion, a price-to-earnings ratio of -117.30 and a beta of 0.41. The company has a current ratio of 2.65, a quick ratio of 2.29 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals has a 1-year low of $377.85 and a 1-year high of $519.88.

Read Our Latest Research Report on VRTX

IQVIA (IQV)

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

IQV traded down $2.37 during trading hours on Friday, reaching $160.88. The company's stock had a trading volume of 2,312,787 shares, compared to its average volume of 1,675,737. The company's 50-day moving average is $152.90 and its 200-day moving average is $170.85. IQVIA has a 52 week low of $134.65 and a 52 week high of $252.88. The firm has a market cap of $27.83 billion, a PE ratio of 21.92, a price-to-earnings-growth ratio of 1.81 and a beta of 1.30. The company has a debt-to-equity ratio of 2.19, a quick ratio of 0.82 and a current ratio of 0.82.

Read Our Latest Research Report on IQV

Cognizant Technology Solutions (CTSH)

Cognizant Technology Solutions Corporation, a professional services company, provides consulting and technology, and outsourcing services in North America, Europe, and internationally. It operates through four segments: Financial Services, Health Sciences, Products and Resources, and Communications, Media and Technology.

Shares of CTSH traded up $0.12 during trading hours on Friday, hitting $75.68. The company had a trading volume of 4,901,713 shares, compared to its average volume of 3,537,882. The firm has a market cap of $37.31 billion, a price-to-earnings ratio of 15.93, a PEG ratio of 1.74 and a beta of 0.96. The company has a quick ratio of 2.22, a current ratio of 2.22 and a debt-to-equity ratio of 0.04. The business has a fifty day moving average of $79.11 and a 200-day moving average of $78.70. Cognizant Technology Solutions has a 12 month low of $65.52 and a 12 month high of $90.82.

Read Our Latest Research Report on CTSH